Insulet Corp (PODD)
246.33
+1.26 (+0.51%)
USD |
NASDAQ |
Oct 06, 09:39
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 17.10B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -14.62% |
| Valuation | |
| PE Ratio | 492.66 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 14.71 |
| Price to Book Value | 40.47 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 3.342 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 41.44% |
News
Headline
Wire
Time (ET)
MT Newswires
09/20 06:25
Yahoo
09/20 06:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 11/03/2022 | -- | Results | Q3 2022 | -- | 0.14 | -- | |
| 11/03/2022 | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 08/04/2022 | -- | Results | Q2 2022 | -0.08 | 0.23 | -133.6% | |
| 08/04/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/05/2022 | -- | Results | Q1 2022 | 0.40 | 0.24 | 68.22% | |
| 05/05/2022 | 16:30 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 02/23/2022 | -- | Results | Q4 2021 | 0.43 | 0.33 | 29.00% | |
| 02/23/2022 | 16:30 EST | Earnings Call | Q4 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 150,000 insulin-dependent diabetics are using it worldwide. |
| URL | https://www.insulet.com |
| Investor Relations URL | https://investor.insulet.com |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Nov. 03, 2022 |
| Last Earnings Release | Aug. 04, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of October 05, 2022.
Fundamentals
| Revenue (TTM) | 1.178B |
| Total Expenses (TTM) | 1.084B |
| Net Income (TTM) | 34.60M |
| Total Assets (Quarterly) | 2.114B |
| Total Liabilities (Quarterly) | 1.691B |
| Shareholders Equity (Quarterly) | 422.40M |
| Cash from Operations (TTM) | -39.70M |
| Cash from Investing (TTM) | -117.40M |
| Cash from Financing (TTM) | 18.80M |
Ratings
Profile
Edit
| Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 150,000 insulin-dependent diabetics are using it worldwide. |
| URL | https://www.insulet.com |
| Investor Relations URL | https://investor.insulet.com |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Nov. 03, 2022 |
| Last Earnings Release | Aug. 04, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| FSMEX | 309.75M USD | 4.07% |
| GDOC | 3.359M USD | 3.35% |
| FSPHX | 244.66M USD | 2.86% |
| FACTX | 164.83M USD | 2.80% |
| NUMG | 6.836M USD | 2.21% |
| ZUH.TO | 7.004M USD | 1.79% |
| IHI | 95.41M USD | 1.62% |
| QQQJ | 11.10M USD | 1.46% |
| BMEZ | 23.90M USD | 1.13% |
| FGCKX | 433.16M USD | 0.99% |
| CSPFX | 561.18M USD | 0.97% |
| CAFFX | 537.85M USD | 0.82% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| PODD Tweets |